Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation): Clinical Trials

1 not yet recruiting. 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	1	Not yet recruiting 1

Follow Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation): new trials by email Literature Review of Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) trials Research Report on Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)	Phase 2	Not yet recruiting	Novartis Pharmaceuticals	51	2026-12-15	2026-09-18

Narrower conditions

Breast Neoplasms (1)

Broader conditions

Breast Diseases (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Skin Diseases (1)  ·  Skin and Connective Tissue Diseases (1)

Interventions

Alpelisib (1)  ·  Fulvestrant (1)  ·  Letrozole (1)  ·  Trastuzumab (1)  ·  pertuzumab (1)

Sponsors

Novartis Pharmaceuticals (1)